Nomifensine

Nomifensine

SCHEMBL49380

CN1Cc2c(N)cccc2C(c2ccccc2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Nomifensine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 15/20 1.00
SLC6A4 known ✓ P31645 15/20 1.00
SLC6A3 known ✓ Q01959 15/20 1.00
LMNA P02545 2/20 1.00
MAPK1 P28482 2/20 1.00
RGS12 O14924 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
ALOX12 P18054 1/20 1.00
NFKB1 P19838 1/20 1.00
HTR2A P28223 1/20 1.00
ADRA1A P35348 1/20 1.00
PTGS2 P35354 1/20 1.00
HRH1 P35367 1/20 1.00
OPRM1 P35372 1/20 1.00
GNAI1 P63096 1/20 1.00
KCNH2 Q12809 1/20 1.00
MEN1 O00255 1/20 0.81
GLA P06280 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nomifensine SCHEMBL125020 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3LMNAMAPK1
Nomifensine SCHEMBL29355061 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3LMNAMAPK1
Nomifensine SCHEMBL11082568 0.98 SLC6A2 (0.97) SLC6A2SLC6A4SLC6A3LMNAMAPK1
Nomifensine SCHEMBL125019 0.90 LMNA (1.00) SLC6A2SLC6A4SLC6A3LMNAMAPK1
Nomifensine SCHEMBL10538258 0.90 LMNA (1.00) SLC6A2SLC6A4SLC6A3LMNAMAPK1
SCHEMBL11013456 0.88 SLC6A2 (0.79) SLC6A2SLC6A4SLC6A3LMNAMAPK1
SCHEMBL9810092 0.87 SLC6A2 (0.77) SLC6A2SLC6A4SLC6A3LMNAMAPK1
SCHEMBL4035368 0.87 SLC6A2 (0.77) SLC6A2SLC6A4SLC6A3LMNAMAPK1
SCHEMBL22400710 0.87 SLC6A2 (0.76) SLC6A2SLC6A4SLC6A3LMNAMAPK1
Bromide SCHEMBL11267146 0.86 SLC6A2 (0.75) SLC6A2SLC6A4SLC6A3LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7661 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106917-A1 EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL BioPhysics Pharma, Inc. (US) 2026-05-21 WO claimed
US-12605345-B2 Transdermal drug delivery system BioPhysics Pharma, Inc. (US) 2026-04-21 US claimed
US-20260001942-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H LUNDBECK AS (DK) 2026-01-01 US claimed
WO-2025262247-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H. LUNDBECK A/S (DK) 2025-12-26 WO claimed
EP-4633638-A1 TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) Luminous Mind Inc. (US) 2025-10-22 EP claimed
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 EP claimed
US-20250268841-A1 Trans-Epithelial Membrane Drug Delivery System Masiz, John J. (US) 2025-08-28 US claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
US-20250120907-A1 Transmucosal Drug Delivery System Masiz, John J. (US) 2025-04-17 US claimed
EP-4525870-A1 METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT Corcept Therapeutics Incorporated (US) 2025-03-26 EP claimed
EP-0161501-B1 ANTI-ULCER MEANS FOR THE TREATMENT OF ABSCESSES T P O "PHARMACHIM" (BG) 1989-03-15 EP claimed
US-4806548-A 4-PHENYL-TETRAHYDROISOQUINOLINE ANTIDEPRESSANT, CIMETIDINE, AND RANITIDINE; HISTAMINE H-2-ANTAGONISTS T P O PHARMACHIM (BG) 1989-02-21 US claimed
CN-1003045-B Synthesis of intermediate amino alcohol of antidepressant Nomifensin TIANJING PHARMACEUTICAL INST S (CN) 1989-01-11 CN claimed
CN-1003013-B Synthesis of nitro acetophenone hydrochloride as intermediate of antidepressant Nomifenin 国家医药管理局天津药物研究院 1989-01-04 CN claimed
WO-1988007684-A2 INFRARED IMMUNOLOGICAL DOSING CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 1988-10-06 WO claimed
CN-86108706-A Synthesizing of alchol of antimelancholic ' Nomifensin ' intermediate nitro-acetophenone hydrochloride 1987-12-23 CN claimed
EP-0161501-A1 Anti-ulcer means for the treatment of abscesses T P O "PHARMACHIM" (BG) 1985-11-21 EP claimed
EP-0089948-B1 PHARMACEUTICAL COMPOSITIONS COPPEN, Alec James (GB) 1985-08-14 EP claimed
EP-0120438-A1 Optical antipodes of 8-amino-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline, process for its preparation and pharmaceutical compositions having an anti-depressive action containing it HOECHST AKTIENGESELLSCHAFT (DE) 1984-10-03 EP claimed
US-4207309-A FOR DIFFERENTIATING BETWEEN HYPERPROLACTINEMIA DUE TO PITUITARY TUMORS AND FUNCTIONAL CASES MULLER EUGENIO E 1980-06-10 US claimed